Unravel Biosciences is an early stage therapeutics company that tackles the biggest source of failure in drug development: lack of efficacy in patients.
We find therapeutic targets that work and patients that respond using proprietary disease maps and RNA data.
Our approach is like a time machine to foresee if a therapy will solve patients’ needs, even for diseases we don't yet understand. We use dynamic RNA data to build unbiased maps of disease using network modeling that generates completely new insights. Our algorithms translate the predicted mechanistic insights into immediately-testable drugs we evaluate in our on-demand animal models of disease. By combining computational analysis with experimental evaluation, we are able to explore the interactions between cells and organs that cause the wide range of symptoms seen in patients, all the way up to the complexities of motion, behavior, and cognition. The rapid integration between computation and experiments allows us to easily iterate the process to identify truly disease-modifying targets.
We find therapeutic targets that work and patients that respond using proprietary disease maps and RNA data.
Our approach is like a time machine to foresee if a therapy will solve patients’ needs, even for diseases we don't yet understand. We use dynamic RNA data to build unbiased maps of disease using network modeling that generates completely new insights. Our algorithms translate the predicted mechanistic insights into immediately-testable drugs we evaluate in our on-demand animal models of disease. By combining computational analysis with experimental evaluation, we are able to explore the interactions between cells and organs that cause the wide range of symptoms seen in patients, all the way up to the complexities of motion, behavior, and cognition. The rapid integration between computation and experiments allows us to easily iterate the process to identify truly disease-modifying targets.
We can't do this alone.
|
We are committed to getting patients effective drugs the fastest way possible. We partner with discovery companies to amplify their strengths through cost-effective decision-making in the areas of target discovery, mechanism identification, drug optimization, and patient stratification for small molecules and biologics.
|